Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Co-Diagnostics Inc Market Cap
From what 1 stock analysts predict, the share price for Co-Diagnostics Inc (CODX) might increase by 68.54% in the next year. This is based on a 12-month average estimation for CODX. Price targets go from $1.5 to $1.5. The majority of stock analysts believe CODX is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
CODX is a stock in Healthcare which has been forecasted to be worth $1.5 as an average. On the higher end, the forecast price is $1.5 USD by Yi Chen from HC Wainwright & Co. and on the lower end CODX is forecasted to be $1.5 by Yi Chen from HC Wainwright & Co..
These are the latest 20 analyst ratings of CODX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Yi Chen HC Wainwright & Co. | Neutral | $1.5 | Reiterates | Nov 11, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | $1.5 | Maintains | Aug 12, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | $2 | Reiterates | Jun 17, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | $2 | Maintains | May 13, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | $2.5 | Maintains | Mar 15, 2024 |
| Yi Chen HC Wainwright & Co. | Neutral | $3 | Reiterates | Dec 29, 2023 |
| Yi Chen HC Wainwright & Co. | Neutral | $3 | Maintains | Nov 13, 2023 |
| Yi Chen HC Wainwright & Co. | Neutral | $2 | Maintains | Aug 14, 2023 |
| Yi Chen HC Wainwright & Co. | Neutral | $3 | Reiterates | May 15, 2023 |
| Yi Chen HC Wainwright & Co. | Neutral | $3 | Downgrade | Mar 20, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Reiterates | Feb 23, 2023 |
| Yi Chen HC Wainwright & Co. | Buy | $6 | Maintains | Nov 14, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $9 | Maintains | Aug 15, 2022 |
| James Sidoti Sidoti & Co. | Neutral | $5 | Downgrade | Aug 12, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $12 | Maintains | May 16, 2022 |
| Yi Chen HC Wainwright & Co. | Buy | $15 | Maintains | Nov 12, 2021 |
Maxim Group | Hold | Downgrade | Mar 29, 2021 | |
| Yi Chen HC Wainwright & Co. | Buy | $16 | Maintains | Mar 26, 2021 |
HC Wainwright & Co. | Buy | $30 | Maintains | Dec 15, 2020 |
HC Wainwright & Co. | Buy | $29 | Maintains | Nov 17, 2020 |
When did it IPO
2017
Staff Count
155
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Dwight H. Egan
Market Cap
$28.4M
In 2023, CODX generated $6.8M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CODX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Co-Diagnostics, Inc. (NASDAQ: CODX) will hold its Q3 2024 results conference call on November 7, 2024, at 4:30 PM ET, featuring CEO Dwight Egan and CFO Brian Brown.
Why It Matters - The Q3 2024 results call for Co-Diagnostics may reveal key financial performance and strategic insights, influencing stock valuation and investor sentiment.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Co-Diagnostics, Inc. reported Q3 2024 revenue of $0.6 million, down from $2.5 million year-over-year, mainly due to timing of grant revenue recognition.
Why It Matters - Co-Diagnostics' significant revenue decline raises concerns about its financial health and growth prospects, potentially impacting stock performance and investor confidence.
Thu, 07 Nov 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Co-Diagnostics, Inc. (CODX) reported a quarterly loss of $0.32 per share, slightly better than the estimated loss of $0.33, and worse than the $0.20 loss per share from the previous year.
Why It Matters - Co-Diagnostics' smaller-than-expected loss may indicate improved operational efficiency. However, the increased loss year-over-year raises concerns about ongoing profitability and growth potential.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Co-Diagnostics, Inc. will showcase its molecular diagnostic tests at MEDICA 2024 in Düsseldorf, Germany, from November 11-14, attracting a large international audience.
Why It Matters - Co-Diagnostics' participation at MEDICA 2024 enhances its visibility, potentially driving partnerships and sales, which can positively impact stock performance and investor sentiment.
Fri, 25 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Co-Diagnostics, Inc. (NASDAQ: CODX) will release its Q3 2024 results on November 7, 2024, after market close, followed by a conference call at 4:30 p.m. the same day.
Why It Matters - Co-Diagnostics' Q3 results release and conference call indicate upcoming insights into financial performance and strategic direction, affecting stock sentiment and investment decisions.
Mon, 21 Oct 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Co-Diagnostics, Inc. will showcase its molecular diagnostic platform at Africa Health/Medlab Africa in Cape Town from October 22-24, 2024, targeting healthcare distributors and executives.
Why It Matters - Co-Diagnostics' participation in a major healthcare conference enhances its visibility and networking potential, possibly leading to new partnerships and increased sales in the growing African market.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
